Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia
This article was originally published in The Pink Sheet Daily
Executive Summary
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.
You may also be interested in...
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.
Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.